ALK and neuroblastoma: Repotrectinib, with a dosage of 12–26 nm, showed sensitivity in ALK WT, G1128A, I1171N, F1174L, R1192P, F1245C, and Y1278S, whereas R1275Q and EML4-ALK secondary mutations resembling G1269A required a larger dosage to suppress Y1604 phosphorylation in neuroblastoma cells.